Bulevirtide monotherapy safe, well-tolerated in chronic hepatitis D patients

LONDON — Bulevirtide induced a greater combined virologic and biochemical response compared with control at 48 weeks in patients with chronic hepatitis D infection, according to research.“HDV causes the most severe form of chronic viral hepatitis with two-to-three-fold increased risk for mortality compared with HBV mono-infection,” Heiner Wedemeyer, PhD, professor and clinical director of gastroenterology, hepatology and endocrinology at Hannover Medical School in Germany, said at the International Liver Congress. “Achieving HDV viral control or cure of chronic HDV isRead More

Related Articles